Equities analysts expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to post earnings per share of $0.20 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Meridian Bioscience’s earnings, with estimates ranging from $0.19 to $0.21. Meridian Bioscience posted earnings of $0.22 per share during the same quarter last year, which would suggest a negative year over year growth rate of 9.1%. The company is scheduled to report its next quarterly earnings results on Thursday, April 26th.
On average, analysts expect that Meridian Bioscience will report full year earnings of $0.71 per share for the current year, with EPS estimates ranging from $0.67 to $0.76. For the next financial year, analysts expect that the company will post earnings of $0.77 per share, with EPS estimates ranging from $0.73 to $0.81. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow Meridian Bioscience.
Meridian Bioscience (NASDAQ:VIVO) last announced its earnings results on Thursday, January 25th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. The firm had revenue of $52.30 million for the quarter, compared to analysts’ expectations of $49.00 million. Meridian Bioscience had a return on equity of 17.00% and a net margin of 10.46%. Meridian Bioscience’s quarterly revenue was up 11.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.15 EPS.
A number of large investors have recently made changes to their positions in the business. Vident Investment Advisory LLC acquired a new stake in Meridian Bioscience during the 4th quarter valued at $217,000. Jane Street Group LLC acquired a new stake in Meridian Bioscience during the 4th quarter valued at $140,000. Millennium Management LLC grew its holdings in Meridian Bioscience by 55.0% during the 4th quarter. Millennium Management LLC now owns 1,133,765 shares of the company’s stock valued at $15,873,000 after buying an additional 402,430 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its holdings in shares of Meridian Bioscience by 642.3% during the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 19,300 shares of the company’s stock worth $270,000 after purchasing an additional 16,700 shares during the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Meridian Bioscience by 27.0% during the fourth quarter. Two Sigma Investments LP now owns 181,944 shares of the company’s stock worth $2,547,000 after purchasing an additional 38,650 shares during the last quarter. Hedge funds and other institutional investors own 85.37% of the company’s stock.
Shares of Meridian Bioscience (NASDAQ VIVO) opened at $14.35 on Monday. The company has a market capitalization of $596.54, a price-to-earnings ratio of 20.74 and a beta of 0.98. The company has a current ratio of 5.82, a quick ratio of 3.96 and a debt-to-equity ratio of 0.28. Meridian Bioscience has a fifty-two week low of $12.45 and a fifty-two week high of $16.45.
The business also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Monday, February 5th will be issued a dividend of $0.125 per share. This represents a $0.50 dividend on an annualized basis and a yield of 3.48%. The ex-dividend date of this dividend is Friday, February 2nd. Meridian Bioscience’s dividend payout ratio (DPR) is presently 98.04%.
COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Earnings of $0.20 Per Share” was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://weekherald.com/2018/02/15/analysts-anticipate-meridian-bioscience-inc-vivo-will-announce-earnings-of-0-20-per-share.html.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.